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ABSTRACT
Health-related quality of life (HRQoL) is an important endpoint, especially in clinical trials for
malignancies with a long course of disease, such as chronic lymphocytic leukemia (CLL). Patient-
reported outcomes were examined in the randomized, double-blind, placebo-controlled HELIOS
study to assess the impact of treatment with the Bruton’s tyrosine kinase inhibitor ibrutinib,
added to bendamustine plus rituximab (BR) background therapy. Measures included FACIT-
Fatigue, EORTC QLQ-C30, QLQ-CLL16, and EQ-5D-5L. Of 578 patients enrolled, 540 (93%) pro-
vided FACIT-Fatigue responses at baseline. Most had only a moderate degree of impairment at
baseline; mean values did not appear to change over time in either treatment arm, suggesting
that adding ibrutinib to BR did not impact health-related quality of life. However, post-hoc
analyses showed that subgroups of patients with the worst fatigue, physical functional status,
and well-being at baseline had greater improvements in these outcomes with ibrutinib plus BR
treatment versus placebo.
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Chronic lymphocytic leukemia (CLL) is the most com-
mon type of leukemia in adults [1]. Early-stage disease
is usually managed with a ‘watch-and-wait’ approach
until it becomes symptomatic, with patients experi-
encing significant weight loss, fatigue, or fever; pro-
gressive bone marrow failure; or symptoms from
lymphadenopathy, splenomegaly, or hepatomegaly
[2,3]. Most conventional CLL therapies contain chemo-
therapeutic agents and may have toxic side effects
and poor tolerability; particularly problematic because
CLL primarily affects the elderly.
The disease-related symptoms, potential toxicity of
therapy, and emotional and socioeconomic aspects of
living with chronic illness can have profound effects
on health-related quality of life (HRQoL) in patients
with CLL [4–6]. As the median age at initial CLL diag-
nosis is 72 years, many patients face further challenges
of managing comorbidities [7]. The most commonly
reported symptom is fatigue [8], a multifaceted phe-
nomenon that reduces patients’ physical energy, men-
tal capacities, and psychological alertness [8–10].
Approximately 9–25% of patients with CLL develop
anemia, which can be caused by bone marrow infiltra-
tion, autoimmune phenomena, or chemoimmuno-
therapy [5]. Anemia also contributes to fatigue and
may cause shortness of breath and lethargy, further
impairing physical functioning and HRQoL. Low-grade
anemia (hemoglobin <12 g/dL) is often associated
with significant reduction in HRQoL [5,11].
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Ibrutinib is a first-in-class, oral, covalent inhibitor of
Bruton’s tyrosine kinase, approved in the United
States, Europe, and many other countries for treatment
of CLL [12,13]. The HELIOS study, a large, international,
double-blind, placebo-controlled phase 3 trial, demon-
strated that the addition of continuous ibrutinib to up
to six cycles of bendamustine plus rituximab (BR) sig-
nificantly improved progression-free survival (PFS)
compared with up to six cycles of BR alone in patients
with relapsed/refractory CLL, with an 80% reduction in
risk of disease progression or death [14]. Although
97% of patients experienced 1 adverse event (mostly
mild/moderate in severity), no unexpected or cumula-
tive toxicities occurred as the safety profile corre-
sponded with toxicity rates previously reported for
both BR chemoimmunotherapy and ibrutinib [15,16].
Increasing PFS and overall survival is the primary
goal of current CLL treatments, but it is also important
to maintain good HRQoL, as patients may live with
their disease for many years. Furthermore, as antineo-
plastic therapies often have side effects, it is essential
to understand the tradeoff between improvements in
disease-related outcomes and any detrimental treat-
ment-related impact on patients’ HRQoL. An under-
standing of patients’ symptoms, functioning, and
overall well-being is valuable to clinicians, patients,
and payers [6]. Patient-reported outcome (PRO) instru-
ments are commonly used to assess patients’ overall
experience in this regard [17], and are increasingly
included as oncology trial endpoints to contextualize
clinical endpoint findings and provide a more compre-
hensive picture of treatment effects [18–22].
To this end, it is imperative that PRO data in oncol-
ogy trials are analyzed and reported in a meaningful
way. Per regulatory guidelines, oncology trials tend to
enroll patients who are expected to benefit from study
treatment and are therefore not too ‘unwell’ [23].
Mean or median changes from baseline in the overall
study population may not accurately reflect outcomes
for smaller subgroups of patients with the worst base-
line HRQoL. Importantly, patients with the greatest
HRQoL impairment at baseline may be those most in
need of a therapy that does not make them feel any
worse.
Initial exploratory analyses in the HELIOS study indi-
cated that, among patients with the worst baseline
fatigue, there were apparent improvements in fatigue
for both treatment groups in the first six cycles (i.e.
while both groups were receiving BR), with signifi-
cantly greater improvements among patients who con-
tinued ibrutinib versus placebo (p< .05 at Cycle 10)
[14]. This analysis aims to further examine the HRQoL
impact of ibrutinib treatment when added to BR
background therapy for patients in the HELIOS study.
Given that initial results suggested a positive treat-
ment effect of ibrutinib plus BR in patients who were
most fatigued at baseline, additional post-hoc analyses
were performed to examine fatigue and other PROs
(e.g. physical functioning, and general well-being),
according to degree of baseline impairment.
Materials and methods
Study design, patients, and treatment
Full details of the HELIOS study design and method-
ology (NCT01611090) have been published previously
[14]. Briefly, adults with CLL or small lymphocytic
lymphoma requiring treatment according to
International Workshop on Chronic Lymphocytic
Leukemia criteria [3], and who had relapsed/refractory
disease following 1 previous therapies, were enrolled
across 133 sites (21 countries). An independent ethics
committee or institutional review board approved the
protocol at each site, and the study was conducted
according to the principles of the Declaration of
Helsinki and Good Clinical Practice guidelines. All
patients provided written informed consent.
Patients were randomized 1:1 to receive oral ibruti-
nib (420mg daily) or placebo in addition to a back-
ground regimen of bendamustine (70mg/m2 on Days
2–3 in Cycle 1 and Days 1–2 in Cycles 2–6) plus rituxi-
mab (375mg/m2 on Day 1 of Cycle 1 and 500mg/m2
on Day 1 of Cycles 2–6) for up to six cycles with a dur-
ation of 28 days. After completion of six cycles,
patients continued to receive ibrutinib or placebo in
28-day cycles until disease progression or unaccept-
able toxicity.
PRO measures
In the HELIOS study, PROs were implemented as sec-
ondary endpoints assessed by a prespecified analysis
plan. PROs were collected using four standardized and
widely accepted instruments for oncology: the
Functional Assessment of Chronic Illness Therapy
(FACIT)-Fatigue scale, the European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (EORTC QLQ)-C30, the EORTC QLQ-CLL
16 (a CLL-specific module), and the EuroQol 5-
Dimension 5-Level questionnaire (EQ-5D-5L) [4,24–28].
In addition to planned analyses on the domains/scales
from each PRO instrument, post-hoc exploratory sub-
group analyses were conducted using all four
instruments to evaluate outcomes according to the
degree of baseline impairment. Correlations between
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fatigue levels, as measured by the FACIT-Fatigue
scale, and hemoglobin levels indicating anemia (hemo-
globin <11 g/dL) were also evaluated as part of the
post-hoc exploratory analysis.
Fatigue
Fatigue was assessed using the FACIT-Fatigue scale, a
13-item instrument designed to specifically assess
aspects of fatigue/tiredness in patients with cancer or
other chronic diseases, including impact on daily activ-
ities and functioning [29]. Several studies of chronic
diseases, including anemia and cancer [30–34], have
shown the FACIT-Fatigue scale can be used to support
valid inferences regarding patient fatigue. Items are
scored on a 0–4 response scale (0¼ not at all; 4¼ very
much), reverse scored where appropriate, and all items
are summed to create a single fatigue score with a
range from 0 to 52, where higher scores indicate bet-
ter functioning or less fatigue. A change of 3 points
is considered clinically meaningful [35].
General cancer assessment, including physical
functioning and well-being
The EORTC QLQ-C30 is a 30-item general cancer
assessment that incorporates five functional scales
(physical, role, emotional, cognitive, and social func-
tioning), three symptom scales (fatigue, nausea/vomit-
ing, and pain), a global health-status and QoL scale
(two items), and six single items (dyspnea, insomnia,
appetite loss, constipation, diarrhea, and financial diffi-
culties). Scores range from 0 to 100 (for functional and
global QoL scales, higher scores indicate a better level
of functioning) [24]. In this analysis, the individual
physical functioning domain was explored; a 10-point
change was considered clinically meaningful [36].
The CLL-specific module QLQ-CLL16 was developed
by the EORTC [37] and comprises 16 questions that
address five domains of HRQoL important in CLL,
including three multi-item scales (fatigue, treatment
side effects and disease symptoms, and infections) and
two single-item scales (social activities and future
health worries) [4,28]. In this analysis, the individual
QLQ-CLL16 item of feeling ill or unwell, which is
measured on a 4-point scale (1¼ not at all; 4¼ very
much), was assessed.
Generic measures of HRQoL and well-being were
also collected using the EQ-5D-5L [38,39]. The EQ-5D-
5L consists of a five-item descriptive system and the
EuroQol visual analog scale (EQ-5D VAS) of self-rated
health, with scores ranging from 0 to 100 (worst to
best imaginable health state). Responses for the five
dimensions are combined into a five-digit number
describing respondents’ health state that can be con-
verted into a single index value or utility score (using
UK weights), ranging from –1 to 1, where lower scores
indicate a worse health status.
PRO instrument administration
PRO instruments were administered to patients at the
beginning of clinic visits to avoid bias from procedures
or physician interactions. Data were collected using
electronic data capture during double-blind treatment
and post-treatment follow-up periods until disease pro-
gression, clinical cutoff, or death. The FACIT-Fatigue and
EORTC QLQ-CLL 16 instruments were administered on
Day 1 of Cycles 1, 2, 4, and 6 (ibrutinib- or placebo-plus-
BR treatment period), Cycles 8 and 10 (ibrutinib- or pla-
cebo-alone treatment period), at the end-of-treatment
visit, and every 12 weeks during the post-treatment fol-
low-up period. The EORTC QLQ-C30 and EQ-5D-5L
instruments were administered on Day 1 of Cycles 1, 3,
and 5 (ibrutinib- or placebo-plus-BR treatment period),
Cycles 7 and 10 (ibrutinib- or placebo-alone treatment
period), at the end-of-treatment visit, and every 12
weeks during the post-treatment follow-up period.
Following disease progression, sites also attempted to
administer the EQ-5D-5L every 16 weeks (up to three
times) in person or via telephone [40].
Statistical analyses
PRO endpoints were analyzed for all patients in the
intent-to-treat population who completed the FACIT-
Fatigue instrument at baseline (Day 1 of Cycle 1) and
had 1 post-baseline value.
The compliance rates of each PRO at each time
point were calculated based on the sample size of
each arm at baseline. Scores from FACIT-Fatigue,
EORTC QLQ-C30, EORTC QLQ-CLL 16, and EQ-5D-5L
were descriptively summarized by treatment group.
Kaplan–Meier curves were generated for FACIT-Fatigue
scores to estimate time to achieve a clinically mean-
ingful change in each treatment group and were com-
pared using a stratified log-rank test.
Subgroup analyses
Individual PROs were evaluated in a post-hoc subgroup
analysis according to degree of HRQoL baseline impair-
ment. The baseline score was defined as the score from
Day 1, Cycle 1. For FACIT-Fatigue, EORTC QLQ-C30
Physical Functioning, and EQ-5D VAS scores, mixed-
model analyses were implemented; patients were
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stratified according to treatment group (ibrutinib/pla-
cebo) and baseline status on that PRO (dichotomized by
most impaired quartile versus the other three quartiles).
For the EORTC QLQ-CLL16 well-being item, patients
were stratified according to treatment group and by
whether they reported feeling ill/unwell ‘quite a bit’ or
‘very much’ at baseline, and for analysis of change over
time, by the proportion of patients achieving a return to
well-being (reported feeling ‘not at all’ ill/unwell). Mean
differences from baseline at each time point between
the two treatment arms were compared statistically
using the mixed-effects model repeated measure
(MMRM) method. This method was implemented using
two stratification factors, treatment and status (worse/
not worse), and included the interaction between treat-
ment and status as covariates in the mixed model. The
association between change in fatigue scores and
hemoglobin levels was examined in patients in the high-
est (most fatigued) quartile of FACIT-Fatigue baseline
scores using linear regression models.
Results
In total, 578 patients were randomized to ibrutinib
plus BR or placebo plus BR in the HELIOS study
(intent-to-treat population, n¼ 289 in each treatment
group). Of these, 540 (93%) provided FACIT-Fatigue
baseline responses and had 1 post-baseline value
(PRO analysis population). Baseline demographic and
clinical characteristics of patients who completed the
FACIT-Fatigue instrument at baseline are shown in
Table 1. Treatment groups were generally well bal-
anced; however, a higher proportion of patients in the
placebo group had Rai stage III/IV disease, hemoglobin
levels indicative of anemia, and low platelet and abso-
lute neutrophil counts, whereas the ibrutinib group
had a higher proportion of patients with bulky disease
and del11q.
Patient-reported outcomes
Baseline HRQoL scores were indicative of a moderate
fatigue level and impaired functioning in the PRO ana-
lysis population: mean baseline FACIT-Fatigue score
was 37.2 (standard deviation [SD] 10.4); mean EORTC-
QLQ-C30 Physical Functioning score was 78.9 (SD
18.9); and mean EQ-5D-5L utility value was 0.79 (SD
0.18). On the EORTC QLQ-CLL 16 instrument, 16.7% of
patients reported feeling ill ‘quite a bit’ or ‘very much’
at baseline.
Prespecified analyses in the overall analysis
population
Overall compliance rates on the PRO instruments
(FACIT-Fatigue, EORTC QLQ-C30, EORTC QLQ-CLL16,
and EQ-5D-5L) were >90%, with <10% missing at
most time points through Cycle 19.
The median time to improvement in FACIT-Fatigue
score was not significantly different in the ibrutinib-
plus-BR and placebo-plus-BR groups: 6.5 versus 4.6
months (hazard ratio 0.853; 95% confidence interval
[CI]: 0.693–1.050). No changes from baseline over time
were observed within or between treatment groups in
mean summary scores on the FACIT-Fatigue scale,
EORTC-QLQ-C30 subscales, EORTC-QLQ-CLL16 items,
EQ-5D-5L utility value, or EQ-5D VAS. However, SDs
were relatively large, and the data trended toward
larger changes at the lower end of the scales, suggest-
ing that data from a majority of patients with small
changes may have masked larger changes in a minor-
ity of patients. Therefore, a subgroup analysis was
undertaken, as described in Materials and methods,
focusing on patients with the worst baseline PRO
scores, who had the greatest potential for HRQoL
improvement.
Subgroup analyses by degree of impairment at
baseline
Among patients who were most fatigued at baseline,
FACIT-Fatigue scores improved by several points fol-
lowing initiation of therapy in both treatment groups
(Figure 1), but to a greater extent overall in the ibruti-
nib-plus-BR group (mean change þ11.21) than in the
placebo-plus-BR group (þ8.57; mean difference 2.64
[95% CI: 0.396–4.879]; p¼ .0212).
Similarly, patients with the greatest impairment in
baseline physical functioning (lowest quartile for
EORTC-QLQ-C30 Physical Functioning score) demon-
strated improvements in functional ability that were
significantly greater with ibrutinib plus BR (mean
Table 1. Demographics and clinical characteristics for patients






Age, mean (SD), years 63.7 (9.69) 63.2 (9.36)
Sex, % male 67.7 65.7
ECOG status (grade 1), % 57.2 56.5
Advanced Rai stage (3–4), % 37.1 (88/237) 46.3 (112/242)
Bulky disease (5 cm), % 58.7 53.5
Del11q, % 29.4 23.2
Mutated IgVH, % 18.9 20.0
No. of prior therapies, median (range) 2.0 (1–11) 2.0 (1–9)
Hemoglobin 11 g/dL, % 26.8 33.6
Platelet count 100,000/mL, % 24.9 29.5
ANC 1500/mL, % 8.2 11.1
ANC: absolute neutrophil count; BR: bendamustine plus rituximab;
Del11q: chromosome 11q deletion; ECOG: Eastern Cooperative Oncology
Group; IgVH: immunoglobulin heavy-chain variable-region; SD: standard
deviation.
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change þ18.7) than with placebo plus BR (þ13.7;
mean difference 5.0 [95% CI: 0.75–9.25]; p¼ .0211)
(Figure 2). Patients in the upper three quartiles (i.e.
least impairment in baseline physical functioning)
showed little mean change over time.
EQ-5D VAS scores (self-rated health status) also
showed improvement over time in the patient quartile
with the lowest baseline scores; this improvement was
not detected in the upper three quartiles, although
the magnitude of improvement in the lowest quartile
did not differ significantly between treatment groups
(mean change þ19.1 versus þ20.7, respectively;
p¼ .5088).
In the 90 patients who reported that they felt ill
‘quite a bit’ or ‘very much’ at baseline, approximately
20–30% achieved a return to well-being (reported feel-
ing ‘not at all’ ill/unwell) by the first visit following
treatment initiation. The proportion of patients achiev-
ing a return to well-being after Cycle 6 (i.e. after the
end of BR background therapy) increased with time on
treatment, to a greater extent in the ibrutinib-plus-BR
group than in the placebo-plus-BR group (Figure 3).
Association between fatigue and hemoglobin
levels
In the HELIOS study, an initial decrease in mean hemo-
globin levels, followed by increasing levels after
treatment Cycles 2–3, was observed in both the ibruti-
nib-plus-BR and placebo-plus-BR groups [14]. In the
subgroup of patients with the worst baseline fatigue,
changes in hemoglobin levels were consistent with
those in the overall patient population, and increased
in alignment with improvements in FACIT-Fatigue
scores (Figure 4). Linear regression analysis of the asso-
ciation between hemoglobin levels and fatigue in this
patient subgroup demonstrated that, during the first
six treatment cycles, when fatigue improved at the
greatest rate, changes in hemoglobin from the previ-
ous cycle significantly predicted concurrent changes in
fatigue in the ibrutinib-plus-BR treatment group (base-
line to Cycle 2 r¼ 0.26; Cycle 2 to Cycle 4 r¼ 0.37, and
Cycle 4 to Cycle 6 r¼ 0.33; p< .05 for all) (Figure 5).
Discussion
The current analysis examined PROs in the HELIOS
study to assess patient well-being and the impact of
treatment with ibrutinib on HRQoL when added to BR
background therapy. In the primary analysis, the addi-
tion of ibrutinib significantly improved PFS and overall
response rate without unexpected or cumulative
toxicities, compared with placebo plus BR in patients
with relapsed/refractory CLL [14]. Consistent with the
study entry criteria and the fact that BR was given as
background therapy, all patients were deemed suitable
Figure 1. Mean (SE) observed change over time in fatigue according to the degree of impairment at baseline. BL: baseline; BR:
bendamustine plus rituximab; EOT: end of trial; SE: standard error. The compliance rates at each time point were calculated based
on the total sample for each treatment arm at baseline.
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for chemoimmunotherapy. This PRO data analysis
showed that most patients entered the trial with only
a moderate degree of fatigue and HRQoL impairment
at baseline, and mean values did not appear to
change over time in either arm. These data indicate
that in the overall patient population there was either
no room for improvement or the addition of ibrutinib
did not improve nor adversely impact HRQoL, thus
supporting a favorable benefit-risk ratio of ibrutinib.
Similar findings were recently reported for the
COMPLEMENT 2 phase 3 trial of patients with relapsed
CLL, which assessed HRQoL outcomes with the add-
ition of ofatumumab to fludarabine plus cyclophos-
phamide. PRO improvements were not significantly
different between treatment arms for global health
status/HRQoL (p¼ .7278) or B symptoms (p¼ .5968),
suggesting that addition of ofatumumab did not have
a negative impact [41].
However, post-hoc analysis of HELIOS data revealed
that among the subgroup of patients with the worst
fatigue, functional status, and well-being at baseline,
greater improvements were achieved with ibrutinib
plus BR. Improvements in fatigue paralleled increases
in hemoglobin levels observed in both treatment
groups (most rapidly during the BR treatment cycles).
Linear regression analysis of the relationship between
changes in hemoglobin level and fatigue score (for
patients in the lowest quartile for baseline fatigue,
regardless of treatment group) confirmed that an
increase in hemoglobin was predictive of fatigue score
improvement.
Because oncology trials tend to enroll patients who
are well enough to benefit from treatment (per regula-
tory requirements), the effects of treatment on HRQoL
Figure 2. Mean (SE) observed change over time in physical functioning according to the degree of impairment at baseline. BL:
baseline; BR: bendamustine plus rituximab; EOT: end of trial; SE: standard error. The compliance rates at each time point were cal-
culated based on the total sample for each treatment arm at baseline.
Figure 3. Changes over time in well-being for patients who
reported feeling quite a bit or very ill/unwell at baseline as
measured by the EORTC QLQ-CLL16 instrument. BR: benda-
mustine plus rituximab; EORTC QLQ-CLL16: European
Organization for Research and Treatment of Cancer Quality of
Life Questionnaire (specific module for symptoms or problems
associated with chronic lymphocytic leukemia).
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may be smaller than if sicker patients are enrolled [20].
This analysis demonstrates how significant improve-
ments achieved in a proportion of patients may have
been masked in the evaluation of PROs based on
mean changes in the whole patient population. This
supports our approach of stratifying patients into
quartiles for analysis of PROs in a population with vari-
able potential for overall improvement. In smaller sam-
ples, it may be appropriate to stratify patients above/
below the median PRO score. Although there are
some limitations to this approach (e.g. appropriate
stratification cutoffs may vary between patient popula-
tions and differ for PRO measures), examining PRO
data in specific subgroups rather than for the whole
population may be a more patient-centered approach
that helps to more fully elucidate the patient experi-
ence. Furthermore, re-evaluation of inclusion criteria in
oncology trials to enroll sicker patients may provide
more representative insight into treatment effects on
‘real-world’ patients [23].
It is important to note that the data should be
interpreted with caution. The subgroups of patients
with the worst fatigue or physical impairment at base-
line were relatively small. Overall, the number of
patients with available data decreased during the fol-
low-up period; hence, the number of patients included
Figure 4. Concurrent mean changes in (A) FACIT-Fatigue scores and (B) hemoglobin levels in patients with high fatigue at base-
line. BR: bendamustine plus rituximab; FACIT: Functional Assessment of Chronic Illness Therapy.
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in the analyses after Cycle 19 is low. The remaining
patients may represent those who responded better to
treatment, or are in remission (patients who pro-
gressed/discontinued are more likely to have dropped
out), which may introduce potential bias toward
patients with better HRQoL scores and longer follow-
up. Although the data suggest that addition of
ibrutinib to BR background therapy had no impact on
patients’ HRQoL in the PRO population, it cannot be
concluded that this remains true after a longer treat-
ment period (e.g. 2 years). Nevertheless, the safety
profile of ibrutinib combined with BR in the HELIOS
study was similar to that of the individual regimens
and there were no unexpected safety signals; as
the observed side effects were not cumulative [14],
HRQoL would not be expected to be detrimentally
affected by drug-related toxicities with ibrutinib added
to BR.
Another limitation to interpretation of this analysis
is that the HELIOS study was not designed to evaluate
ibrutinib as a single agent or with rituximab versus
ibrutinib plus BR. This analysis suggests that fatigue,
physical functioning, and well-being were improved
with the addition of ibrutinib to BR in the worst-
affected patients, in addition to overall improvements
in the quality and duration of treatment response.
However, the question remains whether the BR back-
bone is necessary to achieve these improvements in
this population of relapsed/refractory patients, or alter-
natively, whether BR dampens the HRQoL benefits of
ibrutinib when given in combination.
Although data are limited, the positive impact of
ibrutinib treatment on HRQoL has been reported in
other trials. In a single-arm phase 2 study of ibrutinib
plus rituximab for high-risk CLL, patients showed sig-
nificant improvements in global health status, func-
tioning, and symptom scales on the EORTC-QLQ-C30
at 12 months [42]. In the phase 3 RAY (MCL3001) trial
of patients with relapsed/refractory mantle cell lymph-
oma, ibrutinib monotherapy was associated with
improved Functional Assessment of Cancer Therapy-
Lymphoma (FACT-Lym) subscale and total scores, as
well as EQ-5D-5L utility and EQ-5D VAS scores, com-
pared with temsirolimus [43].
In conclusion, the results of this post-hoc analysis of
the HELIOS study highlight that, although most
patients had relatively good baseline HRQoL scores,
patients with greater impairments or worse HRQoL
cannot be overlooked, as they in particular require
therapies that are well tolerated and do not further
impair their HRQoL. In the HELIOS study, ibrutinib
treatment added to a background BR regimen not
only improved PFS and duration of treatment response
in the overall study population, but also improved
fatigue, physical functioning, and well-being in CLL
patients with the greatest baseline deficits in these
HRQoL domains. These findings emphasize the
need for therapies that are both efficient and well tol-
erated for patients with poor functional status related
to CLL.
Figure 5. Correlation between improvements in FACIT-Fatigue
score and hemoglobin levels in patients with high fatigue at
baseline. BR: bendamustine plus rituximab; FACIT: Functional
Assessment of Chronic Illness Therapy.
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